Sequenom Inc. Gets FDA Letter on SEQureDx; FDA Approval Required Before Genetic Test Sold

Reuters -- Sequenom Inc (SQNM.O) said it received a letter from U.S. health regulators on the use of its prenatal genetic test, which detects fetal gene and chromosome abnormalities in pregnant women.
MORE ON THIS TOPIC